AnaptysBio Q1 2024 Earnings Report

AnaptysBio EPS Results

• Actual EPS: -$1.64
• Consensus EPS: -$1.54
• Beat/Miss: Missed by -$0.10
• One Year Ago EPS: N/A

AnaptysBio Revenue Results

• Actual Revenue: $7.18 million
• Expected Revenue: $4.55 million
• Beat/Miss: Beat by +$2.63 million
• YoY Revenue Growth: N/A

AnaptysBio Announcement Details

• Quarter: Q1 2024
• Date: 5/9/2024
• Time: N/A

AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.